All In Biotech

Drug Trial Radar · NCT04678739

Efficacy and Safety of Remdesivir and Tociluzumab for the Management of Severe COVID-19: A Randomized Controlled Trial

Last checked: Nov 19, 2026Latest source record: Apr 2, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 205 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

205

Actual

Start

Aug 15, 2020

Primary completion

Jan 30, 2021

Study completion Feb 10, 2021

Sponsor

Lead sponsor
M Abdur Rahim Medical College and HospitalGovernment (non-federal)
Sponsor type
Government (non-federal)
Collaborators
First Affiliated Hospital Xi'an Jiaotong University; Cox's Bazar 250 Bed District Sadar Hospital; Chattogram General Hospital
First posted
Dec 22, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 16 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized clinical trial was designed and intended to evaluate the efficacy of Remdesivir and Tocilizumab as a treatment for severe Acute Respiratory Distress Syndrome (ARDS) caused by Coronavirus disease 2019 (COVID-19). Our aim is to find the best option for the treatment and management of ARDS in COVID-19 patients.

Conditions

  • Covid19
  • Covid-19 ARDS

Interventions

  • RemdesivirDrug

    Remdesivir 100 IV Infusion as a lyophilized powder

  • TocilizumabDrug

    Actemra IV Infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to Clinical Improvement (TTCI)Time frame: Following randomization 30 days.

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Chattogram General Hospital

    Chittagong, Bangladesh

  • Cox's Bazar 250 Bed District Sadar Hospital

    Cox’s Bāzār, Bangladesh

  • M. Abdur Rahim Medical College Hospital

    Dinajpur, Bangladesh

  • M. Abdur Rahim Medical College Hospital

    Dinajpur, Bangladesh

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.